NEG+ Innovations is led by a physician-scientist with deep translational medicine, oncology drug development, and medical device expertise — supported by an advisory board assembled for complete commercialization coverage across regulatory, clinical, engineering, and capital domains.
Dr. Jimmy Belotte is a board-certified OB/GYN, physician-scientist, and inventor whose work sits at the intersection of women's health surgical innovation, translational medicine, and medical device entrepreneurship. As Medical Director, Oncology Clinical Development at GlaxoSmithKline, he leads regulatory strategy and protocol design across Phase I/II gynecologic oncology programs — directly informing NEG+'s clinical development and regulatory approach within the broader women's health landscape.
Dr. Belotte's academic foundation — including a PhD in Molecular Medicine and an MBA with concentrations in healthcare and finance — positions him at the intersection of clinical rigor, translational science, and venture-grade business execution. As both inventor and co-investor in NEG+ Innovations, he brings the rare combination of hands-on surgical insight and capital commitment that defines founder-led medtech. As Clinical Associate Professor at Albert Einstein College of Medicine, he maintains active academic clinical relationships that serve as the backbone of NEG+'s investigator network and NIH STTR academic partnership strategy.
NEG+ Innovations was built from a clinical problem-first perspective: each device in the portfolio emerged directly from documented deficiencies Dr. Belotte encountered in women's health surgical practice — then validated through voice-of-customer research, engineering feasibility, and market analysis before a single patent was filed. Every invention carries both his intellectual and financial conviction.
NEG+ Innovations is governed by a Board of Directors combining physician-scientist founding leadership with deep technology commercialization, precision engineering, and life science instrumentation expertise.
Physician-scientist and serial medtech entrepreneur. Board-certified OB/GYN and gynecologic oncologist; Medical Director, Oncology Clinical Development at GlaxoSmithKline; Clinical Associate Professor, Albert Einstein College of Medicine / Montefiore. PhD in Molecular Medicine. MBA with concentrations in healthcare and finance. Founded NEG+ from documented clinical unmet needs across the women's pelvic health surgical and diagnostic landscape.
Executive Resume →Serial life science technology CEO with a PhD and MS from MIT (Precision Engineering Research Group) and an MBA from MIT Sloan Fellows. Current CEO of Kytopen (cell engineering platform). Prior CEO of Erbi Biosystems, acquired by Merck KGaA / MilliporeSigma. Former CTO and executive at Automation Engineering Inc. (acquired by Mycronic AB) and Teradyne. Nine patents across precision engineering, medical devices, and cell therapy. R&D 100 Award recipient.
LinkedIn Profile →This board seat is reserved for an independent director whose expertise will complement the existing governance composition. Announcement forthcoming.
NEG+ has assembled a multi-disciplinary Advisory Board spanning FDA regulatory strategy, clinical validation, engineering execution, investor access, life sciences partnerships, health economics, and corporate finance — each member occupying a defined, non-redundant value lane built for full commercialization coverage.
Exceptional regulatory access and strategic pathway expertise — a resource most medtech startups at any stage do not have. Key lane: 510(k) / De Novo / IDE strategy.
Clinical champion for POP-Q AutoSense™ and Belotte Colpotomizer™. Reduces IDE activation friction; serves as STTR PI candidate at an established NIH-funded institution.
Urogynecologist and URPS specialist at Beth Israel Deaconess Medical Center, a Harvard Medical School–affiliated academic medical center. Scientific Advisor and prospective STTR academic PI for the POP-Q AutoSense™ program. 20+ years of practice with a peer-reviewed publication record directly encompassing POP-Q methodology, prolapse staging accuracy, voiding dysfunction, and surgical outcomes.
Mechanical engineering execution, FDA design controls (21 CFR Part 820), ISO 13485 QMS implementation, and Design History File architecture.
Medtech angel and early-stage VC network access. Investor relations strategy, pitch positioning, and seed round pipeline for Series Seed target investors.
Corporate venture capital and biopharma strategic partnership lane. Growth-stage business development relationships and strategic acquirer relationship development.
Healthcare economics, reimbursement strategy, CPT code development pathway, and SBIR/STTR narrative framework for NIH Specific Aims alignment.
Investor governance, SAFE documentation, cap table management, IP agreement architecture, and Series Seed transaction readiness for institutional venture investors.
Professor and Associate Vice Chair, Department of OB/GYN and Women's Health, Albert Einstein College of Medicine / Montefiore Medical Center. Director of Minimally Invasive Gynecologic Surgery; Co-Fellowship Program Director, MIGS. 37 years of clinical practice with an extensive peer-reviewed publication record in gynecologic surgery. Co-investigator candidate for Belotte Colpotomizer™ MIGS feasibility studies.
MIT-trained engineer with 25+ years developing medical devices across pharmaceutical, medtech, and life science instrumentation sectors. CTO at Kytopen; former VP Product Development. Brings precision engineering execution, R&D team architecture, and product-to-market leadership directly applicable to NEG+'s device development programs.
Deep expertise in continuous bioprocessing, bioreactor technology, and cell therapy engineering with an extensive European biotech and biopharma network. Fluent in French and Swedish. Supports NEG+'s bioprocess-adjacent partnerships and international business development strategy across European pharmaceutical and life science markets.
"In more than two decades of urogynecologic practice, I have witnessed firsthand how subjective POP-Q examination leads to inconsistent staging — and, ultimately, inconsistent patient care. The POP-Q Sensorized Device™ represents a meaningful step toward the objective, reproducible pelvic floor assessment our field has long needed. I am committed to supporting its rigorous clinical validation at BIDMC and to advancing a platform that can meaningfully improve outcomes for women with pelvic organ prolapse."
We welcome collaboration with leading research institutions, clinical investigators, industry partners, and accredited investors who share our commitment to advancing women's health through precision medical technology.